No two projects will ever be the same, but there are commonly recurring issues that hinder progress towards a strong candidate molecule. Sygnature can draw on the past experience of over 180 drug discovery client projects and the collective industry expertise of our senior scientists to focus efforts on solving the key issues in your project.
Sygnature’s project leaders and scientists recognise that a combination of expert science and transparent communication are the only way to succeed in collaborative drug discovery. Our project leaders and teams work together with our clients to provide a collaborative, scientifically robust environment that creates success and rapidly identifies dead-end series.
Success can be viewed in different ways. Whilst we all strive to discover new innovative medicines, quickly disproving a hypothesis can be extremely valuable. For example, demonstrating that a compound does not bind specifically to a target protein, allows project teams to re-focus efforts on better hits and spend budgets effectively.
Transparency is key
Our project teams are led by experienced laboratory-based project leaders that are dedicated to one client’s project. We don’t require our project leaders to manage multiple projects. Each team member will be assigned to client’s project for its duration with changes occurring only in exceptional circumstances. In addition, each project has a highly experienced director assigned to add scientific and executive management expertise.
Whether a small or large project, Sygnature’s scientist will communicate regularly via multiple channels. When challenges occur some CROs have a reputation for communicating less; Sygnature prides itself on doing the opposite. Our state of the art IT infrastructure facilitates effective communication and idea generation across the globe.
Syganture’s scientists have a track record of delivering robust clinical candidates. Since 2011 we have contributed to the delivery of thirty such candidates, fourteen of which have already progressed and are currently undergoing clinical trials. Sygnature’s intellectual contributions to client’s project innovation are acknowledged in the form of patent application – greater than forty applications so far.